Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis

References

• Abtahi Froushani SM, Delirezh N, Hobbenaghi R, Mosayebi G. (2014). Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis. Immunol Invest, 43, 54–68
   PubMed Web of Science ®Google Scholar
• Bai S, Li Y, Wang J, et al. (2011). Modeled microgravity suppressed expansion of the MBP-specific T lymphocytes of rats with EAE. Immunol Invest, 40, 535–51
   PubMed Web of Science ®Google Scholar
• Bayless KJ, Meininger GA, Scholtz JM, Davis GE. (1998). Osteopontin is a ligand for the αβ1 integrin. J Cell Sci, 111, 1165–74
   PubMed Web of Science ®Google Scholar
• Bittner S. (2012). The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Exp Neurol, 238, 149–55
   PubMed Web of Science ®Google Scholar
• Bittner S, Afzali AM, Wiendl H, Meuth SG. (2014). Myelin oligodendrocyte glycoprotein (MOG35–55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Vis Exp, 86, e51275
   Google Scholar
• Chames P, Regenmortel MV, Weiss E, Baty D. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol, 157, 220–33
   PubMed Web of Science ®Google Scholar
• Chigaev A, Sklar LA. (2012). Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. Front Immunol, 3, 242
   PubMed Web of Science ®Google Scholar
• Coisne C, Mao W, Engelhardt B. (2009). Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the BBB in vivo in an animal model of multiple sclerosis. J Immunol, 182, 5909–13
   PubMed Web of Science ®Google Scholar
• Cox D, Brennan M, Moran N. (2010). Integrins as therapeutic targets: Lessons and opportunities. Nat Rev Drug Discov, 9, 804–20
   PubMed Web of Science ®Google Scholar
• Davenport RJ, Munday JR. (2007). Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Dis Today, 12, 569–76
   PubMed Web of Science ®Google Scholar
• de Andres C, Teijeiro R, Alonso B, et al. (2012). Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One, 7, e34103
   PubMed Web of Science ®Google Scholar
• Dong XW, Du XG, Zhang SJ, et al. (2008). Inhibitory effects of BIO-1211 on bronchoconstriction and neutrophil adhesion in rats. Zhejiang Da Xue Xue Bao Yi Xue Ban, 37, 340–4
   PubMedGoogle Scholar
• Engelhardt B, Ransohoff RM. (2005). The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol, 26, 485–95
   PubMed Web of Science ®Google Scholar
• Evans R, Patzak I, Svensson L. (2009). Integrins in immunity. J Cell Sci, 122, 215–25
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. (2006). Medical progress: Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med, 354, 942–55
   PubMed Web of Science ®Google Scholar
• Girolamo F, Ferrara G, Strippoli M, et al. (2011). Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. Neurobiol Dis, 43, 678–89
   PubMed Web of Science ®Google Scholar
• Gold R, Linington C, Lassmann H. (2006). Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in EAE research. Brain, 129, 1953–71
   PubMed Web of Science ®Google Scholar
• Handel AE, Lincoln MR, Ramagopalan SV. (2011). Of mice and men: Experimental autoimmune encephalitis and multiple sclerosis. Eur J Clin Invest, 41, 1254–8
   PubMed Web of Science ®Google Scholar
• He YX, Du M, Gao Y, et al. (2013). Astragaloside IV attenuates EAE of mice by counteracting oxidative stress at multiple levels. PLoS One, 8, e76495
   PubMed Web of Science ®Google Scholar
• Heidary M, Rakhshi N, Pahlevan Kakhki M, et al. (2014). The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients. J Neuro Sci, 343, 41–5
   PubMed Web of Science ®Google Scholar
• Imai Y, Shimaoka M, Kurokawa M. (2010). Essential roles of VLA-4 in the hematopoietic system. Int J Hematol, 91, 569–75
   PubMed Web of Science ®Google Scholar
• Jackson DY. (2002). Alpha 4 integrin antagonists. Curr Pharma Design, 8, 1229–53
   PubMed Web of Science ®Google Scholar
• Karanam BV, Javrai A, Rabe M, et al. (2007). Effect of enalapril on the in vitro and in vivo peptidyl cleavage of a potent VLA4 antagonist. Xenobiotica, 37, 487–502
   PubMed Web of Science ®Google Scholar
• Kawamoto E, Nakahashi S, Okamoto T, et al. (2012). Anti-integrin therapy for multiple sclerosis. J Autoimmune Dis, 2012, 357101
   Google Scholar
• Kent SJ, Karlik SJ, Cannon C, et al. (1995). A monoclonal antibody to alpha 4 integrin suppresses and reverses active EAE. J Neuroimmunol, 58, 1–10
   PubMed Web of Science ®Google Scholar
• Kenyon NJ, Liu R, Roark EM, et al. (2009). An alpha 4 beta 1 integrin antagonist decreases airway inflammation in ovalbumin exposed mice. Eur J Pharmacol, 603, 138–46
   PubMed Web of Science ®Google Scholar
• Kim C, Ye F, Ginsberg MH. (2011). Regulation of integrin activation. Annu Rev Cell Dev Biol, 27, 321–45
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl I, Kumpfel T, et al. (2008). Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology, 71, 1350–4
   PubMed Web of Science ®Google Scholar
• Kuerten S, Kostova-Bales DA, Frenzel LP, et al. (2007). MP4- and MOG:35–55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol, 189, 31–40
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Popescu BF, Bunyan RF, et al. (2011). Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med, 365, 2188–97
   PubMed Web of Science ®Google Scholar
• Mangiardi M, Crawford DK, Xia X, et al. (2011). An animal model of cortical and callosal pathology in multiple sclerosis. Brain Pathol, 21, 263–78
   PubMed Web of Science ®Google Scholar
• Merkler D, Ernsting T, Kerschensteiner M, et al. (2006). A new focal EAE model of cortical demyelination: Multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain, 129, 1972–83
   PubMed Web of Science ®Google Scholar
• Miller SD, Karpus WJ, Davidson TS. (2007). Experimental autoimmune encephalomyelitis in the mouse. Current Protocols in Immunology, Chapter 15, Unit 15.1
   Google Scholar
• Mindur JE, Ito N, Dhib-Jalbut S, Ito K. (2014). Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE. PLoS One, 9, e99068
   PubMed Web of Science ®Google Scholar
• Moon C, Ahn M, Jeong C, et al. (2011). Immunohistochemical study of netrin-1 in the spinal cord with rat experimental autoimmune encephalomyelitis. Immunol Invest, 40, 160–71
   PubMed Web of Science ®Google Scholar
• Muller DM, Pender MP, Greer JM. (2000). A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol, 100, 174–82
   PubMed Web of Science ®Google Scholar
• Muro F, Iimura S, Sugimoto Y, et al. (2009a). Discovery of Trans-4-[1-[[2, 5-Dichloro-4-(1-methyl-3-indolylcarboxamido) phenyl] acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy] cyclohexanecarboxylic acid: An orally active, selective very late antigen-4 antagonist. J Med Chem, 52, 79–4
   Web of Science ®Google Scholar
• Muro F, Iimura S, Yoneda Y, et al. (2008). Identification of 4-[1-[3-chloro-4-[N’-(5-fluoro-2-methylphenyl) ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy] benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem, 16, 9991–10000
   PubMed Web of Science ®Google Scholar
• Muro F, Iimura S, Yoneda Y, et al. (2009b). A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid. Bioorg Med Chem, 17, 1232–43
   PubMed Web of Science ®Google Scholar
• Niino M, Bodner C, Simard ML, et al. (2006). Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol, 59, 748–54
   PubMed Web of Science ®Google Scholar
• Paskowitz DM, Nguyen QD, Gehlbach P, et al. (2012). Safety, tolerability, and bioavailability of topical SAR (1118), a novel antagonist of lymphocyte function-associated antigen-1: A phase1b study. Eye, 26, 944–9
   PubMed Web of Science ®Google Scholar
• Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. (2007). A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies. J Neurosci Meth, 163, 245–54
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdová E, et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 354, 899–910
   PubMed Web of Science ®Google Scholar
• Pomeroy IM, Matthews PM, Frank JA, et al. (2005). Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain, 128, 2713–21
   PubMed Web of Science ®Google Scholar
• Putzki N, Baranwal MK, Tettenborn B, et al. (2010). Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol, 63, 311–17
   PubMed Web of Science ®Google Scholar
• Radue EW, Stuart WH, Calabresi PA, et al. (2010). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci, 292, 28–35
   PubMed Web of Science ®Google Scholar
• Ramroodi N, Niazi AA, Sanadgol N, et al. (2013). Evaluation of reactive Epstein–Barr virus (EBV) in Iranian patient with different subtypes of multiple sclerosis. Braz J Infect Dis, 17, 156–63
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. (2007). Natalizumab for multiple sclerosis. N Engl J Med, 356, 2622–9
   PubMed Web of Science ®Google Scholar
• Rasmussen S, Wang Y, Kivisäkk P, et al. (2007). Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing–remitting experimental autoimmune encephalomyelitis. Brain, 130, 2816–29
   PubMed Web of Science ®Google Scholar
• Reich M, Liefeld T, Gould J, et al. (2006). GenePattern 2.0. Nat Genet, 38, 500–1
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. (2004). Natalizumab: Alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother, 4, 571–80
   PubMedGoogle Scholar
• Sanadgol N, Mostafaie A, Bahrami G, et al. (2010). Elaidic acid sustains LPS and TNF-alpha induced ICAM-1 and VCAM-I expression on human bone marrow endothelial cells (HBMEC). Clin Biochem, 43, 968–72
   PubMed Web of Science ®Google Scholar
• Sanadgol N, Mostafaie A, Mansouri K, Bahrami GH. (2012). Effect of palmitic acid and linoleic acid on expression of ICAM-1 and VCAM-1 in human bone marrow endothelial cells. Arch Med Sci, 8, 192–8
   PubMed Web of Science ®Google Scholar
• Sanadgol N, Ramroodi N, Ahmadi GA, et al. (2011). Prevalence of cytomegalovirus infection and its role in total immunoglobulin pattern in Iranian patients with different subtypes of multiple sclerosis. New Microbiol, 34, 263–74
   PubMed Web of Science ®Google Scholar
• Sanchooli J, Ramroodi N, Sanadgol N, et al. (2014). Relationship between metalloproteinase 2 and 9 concentrations and soluble CD154 expression in Iranian patients with multiple sclerosis. Kaohsiung J Med Sci, 30, 235–42
   PubMed Web of Science ®Google Scholar
• Setoguchi M, Iimura S, Sugimoto Y, et al. (2013). A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: Trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl] acetyl]-(5S)-[methoxy (methyl) amino] methyl-(2S)-pyrrolidinylmethoxy] cyclohexanecarboxylic acid. Bio Med Chem, 21, 42–61
   PubMed Web of Science ®Google Scholar
• Shin T, Kim S, Moon C. (2000). Aminoguanidine-induced amelioration of autoimmune encephalomyelitis is mediated by reduced expression of inducible nitric oxide synthase in the spinal cord. Immunol Invest, 29, 233–41
   PubMed Web of Science ®Google Scholar
• Shin T, Matsumoto Y. (2001). A quantitative analysis of CD45Rlow CD4+ T cells in the subarachnoid space of Lewis rats with autoimmune encephalomyelitis. Immunol Invest, 30, 57–64
   PubMed Web of Science ®Google Scholar
• Solati Sarvandi S, Joghataei MT, Parivar K, et al. (2015). In vitro differentiation of rat mesenchymal stem cells to hepatocyte lineage. Iran J Basic Med Sci, 18, 89–97
   PubMed Web of Science ®Google Scholar
• Stasiolek M, Bayas A, Kruse N, et al. (2006). Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain, 129, 1293–305
   PubMed Web of Science ®Google Scholar
• Stephen DM, William JK, Todd SD. (2007). Experimental autoimmune encephalomyelitis in the mouse. In: Current Protocol Immunology
   Google Scholar
• Storch MK, Bauer J, Linington C, et al. (2006). Cortical demyelination can be modeled in specific rat models of autoimmune encephalomyelitis and is major histocompatability complex (MHC) haplotype-related. J Neuropathol Exp Neurol, 65, 1137–42
   PubMed Web of Science ®Google Scholar
• Takayama G, Matsumoto K, Taira T, et al. (2013). Improvement of pulmonary function by oral treatment with a VLA-4 antagonist in a mouse asthmatic model. J Pharmacol Sci, 121, 172–5
   PubMed Web of Science ®Google Scholar
• Tambalo S, Peruzzotti-Jametti L, Rigolio R, et al. (2015). Functional magnetic resonance imaging of rats with EAE reveals brain cortex remodeling. J Neurosci, 35, 10088–100
   PubMed Web of Science ®Google Scholar
• Theien BE, Vanderlugt CL, Nickerson-Nutter C, et al. (2003). Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood, 15, 4464–71
   Web of Science ®Google Scholar
• Trapp BD, Nave KA. (2008). Multiple sclerosis: An immune or neurodegenerative disorder. Annu Rev Neurosci, 31, 247–69
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Laschinger M, Engelhardt B. (2001). Alpha4-integrein-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest, 108, 557–65
   PubMed Web of Science ®Google Scholar
• Vanderslice P, Woodside DG, Caivano AR, et al. (2010). Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha 4 beta1. Biochem Biophys Res Commun, 400, 619–24
   PubMed Web of Science ®Google Scholar
• Wang D, Lu Z, Hu L, et al. (2009). Macrolide antibiotics aggravate experimental autoimmune encephalomyelitis and inhibit inducible nitric oxide synthase. Immunol Invest, 38, 602–12
   PubMed Web of Science ®Google Scholar
• Wolf C, Sidhu J, Otoul C, et al. (2013). Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: A randomized, double-blind phase 1/2 Study. PLoS One, 8, e58438
   PubMed Web of Science ®Google Scholar
• Woodside DG, Vanderslice P. (2008). Cell adhesion antagonists: Therapeutic potential in asthma and chronic obstructive pulmonary disease. Bio Drugs, 22, 85–100
   Google Scholar
• Yaldizli O, Putzki N. (2009). Natalizumab in the treatment of MS. Ther Adv Neurol Disord, 2, 115–28
   PubMedGoogle Scholar
• Yednock TA, Cannon C, Fritz LC. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature, 356, 63–6
   PubMed Web of Science ®Google Scholar
• Yonekawa K, Harlan JM. (2005). Targeting leukocyte integrins in human diseases. J Leukoc Biol, 77, 129–40
   PubMed Web of Science ®Google Scholar
• Zoghi S, Amirghofran Z, Nikseresht A, et al. (2011). Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters. Immunol Invest, 40, 581–96
   PubMed Web of Science ®Google Scholar